Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
CancerPediatric drugs

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) included InnoCare's ICP‑B794 and Hiteck Biological's Aponermin in the "Care Program – Extension" pilot project, while Genhouse…

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Nationally negotiated drugs

Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products

Patents

CNIPA Releases Updated Patent Law Rules with Pharma Industry in Focus

CDE

China’s CDE Issues Draft Guidelines for Overseas Drug Market Approval Filings

NHC (NHFPC)

China Announces New Hospital Inspection Measures to Standardize Healthcare System

Show More